Introduction
Bronchiectasis is a chronic respiratory condition characterized by irreversible dilation of bronchi, leading to recurrent infections, persistent inflammation, and progressive lung damage. Among pathogens implicated in bronchiectasis exacerbations, Pseudomonas aeruginosa (PA) holds a pivotal role due to its association with poorer clinical outcomes. However, clinical manifestations and responses to treatment in PA-colonized patients vary substantially, reflecting underlying microbial and host heterogeneity. Understanding the ecological and functional diversity of PA within the airway microbiome may clarify drivers of disease variability and guide tailored therapeutic strategies.
